Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Tang

Showing results (131-140 of 221) with videos related to

Pageof 23
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 6, 2019
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical TrialDario Pasalic, Deborah A Kuban, Pamela K Allen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 8, 2023
Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional studyChad Tang, Jeremiah Sanders, Howard Thames, et al.
Brachytherapy|January 4, 2025
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrencesComron Hassanzadeh, Osama Mohamad, Teresa Bruno, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2024
Validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic body radiationMarcus A Florez, Brian De, Roman Kowalchuk, et al.
BJU International|April 14, 2023
Definitive local therapy for T4 prostate cancer associated with improved local control and survivalLauren M Andring, Ibrahim Abu-Gheida, Tharakeswara Bathala, et al.
Urologic Oncology|February 11, 2022
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombusYuval Freifeld, Ivan Pedrosa, Mark Mclaughlin, et al.
Scientific Reports|February 2, 2018
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung CancerChad Tang, Brian Hobbs, Ahmed Amer, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
The Lancet. Oncology|October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Pageof 23

Showing results (131-140 of 221) with videos related to

Sort By:
Pageof 23
International Journal of Radiation Oncology, Biology, Physics|March 6, 2019
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical TrialDario Pasalic, Deborah A Kuban, Pamela K Allen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 8, 2023
Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional studyChad Tang, Jeremiah Sanders, Howard Thames, et al.
Brachytherapy|January 4, 2025
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrencesComron Hassanzadeh, Osama Mohamad, Teresa Bruno, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2024
Validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic body radiationMarcus A Florez, Brian De, Roman Kowalchuk, et al.
BJU International|April 14, 2023
Definitive local therapy for T4 prostate cancer associated with improved local control and survivalLauren M Andring, Ibrahim Abu-Gheida, Tharakeswara Bathala, et al.
Urologic Oncology|February 11, 2022
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombusYuval Freifeld, Ivan Pedrosa, Mark Mclaughlin, et al.
Scientific Reports|February 2, 2018
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung CancerChad Tang, Brian Hobbs, Ahmed Amer, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
The Lancet. Oncology|October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Pageof 23